Skip to main content
Premium Trial:

Request an Annual Quote

Transgenomic Sees Q4 Revenues Decline, Negotiates $2.75M Convertible Note

NEW YORK, Feb. 24 (GenomeWeb News) - Transgenomic today reported a 7 percent drop in fourth-quarter revenues year over year, coupled with narrowed net losses, lower R&D spending, and dwindling cash reserves.

The company's revenues for the fourth quarter ended Dec. 31, 2003, were $8.5 million, down from $9.2 million in the year-ago period.

Transgenomic's net loss for the quarter, including a goodwill impairment charge of $4.8 million, was $8.5 million, or $.32 per share. This was down from a net loss of $9.3 million, or $.40 per share, in the fourth quarter of 2002, which included restructuring charges of $3.3 million.

Transgenomic spent $2.2 million on R&D during the quarter, down 33 percent from $3.3 million in the fourth quarter of 2002.

The company had $1.2 million in cash, cash equivalents, and short-term investments as of Dec. 31, 2003, compared to $13.3 million at the close of 2002.

CFO Michael Draper said that the company has abandoned its previous plans to improve its liquidity position, which involved a sale-and-leaseback transaction related to its Glasgow, Scotland, manufacturing facility. Instead, the company will broaden a $7.5 million credit facility it established with Laurus Master Fund in December to include a three-year, $2.75 million convertible note. Draper said the arrangement "is preferable to the sale and leaseback options available" and "will be adequate to support our operations," based on current projections.

The Scan

Drug Response Variants May Be Distinct in Somatic, Germline Samples

Based on variants from across 21 drug response genes, researchers in The Pharmacogenomics Journal suspect that tumor-only DNA sequences may miss drug response clues found in the germline.

Breast Cancer Risk Gene Candidates Found by Multi-Ancestry Low-Frequency Variant Analysis

Researchers narrowed in on new and known risk gene candidates with variant profiles for almost 83,500 individuals with breast cancer and 59,199 unaffected controls in Genome Medicine.

Health-Related Quality of Life Gets Boost After Microbiome-Based Treatment for Recurrent C. Diff

A secondary analysis of Phase 3 clinical trial data in JAMA Network Open suggests an investigational oral microbiome-based drug may lead to enhanced quality of life measures.

Study Follows Consequences of Early Confirmatory Trials for Accelerated Approval Indications

Time to traditional approval or withdrawal was shorter when confirmatory trials started prior to accelerated approval, though overall regulatory outcomes remained similar, a JAMA study finds.